Diabetes Metab J.
2024 Jan;48(1):159-160. 10.4093/dmj.2022.0458.
Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition (Diabetes Metab J 2023;47:784-95)
- Affiliations
-
- 1Division of Life Sciences, College of Life Sciences and Bioengineering, Incheon National University, Incheon, Korea
- 2Department of Biological Science, University of Ulsan, Ulsan, Korea
- 3Division of Sport Science, College of Arts & Physical Education, Incheon National University, Incheon, Korea
- 4Department of Nano-Bioengineering, College of Life Science and Technology, Incheon National University, Incheon, Korea
- 5Research Center of Brain-Machine Interface, Incheon National University, Incheon, Korea
- 6Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
- KMID: 2551272
- DOI: http://doi.org/10.4093/dmj.2022.0458
Reference
-
1. Lee HG, Jung IH, Park BS, Yang HR, Kim KK, Tu TH, et al. Altered metabolic phenotypes and hypothalamic neuronal activity triggered by sodium-glucose cotransporter 2 inhibition. Diabetes Metab J. 2023; 47:784–95.2. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016; 18:783–94.3. Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities. Obes Rev. 2019; 20:816–28.4. Lu K, Chen X, Yan J, Li X, Huang C, Wan Q, et al. The effect of feeding behavior on hypothalamus in obese type 2 diabetic rats with glucagon-like peptide-1 receptor agonist intervention. Obes Facts. 2018; 11:181–94.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition (Diabetes Metab J 2023;47:784-95)
- Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition
- Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
- Sodium-Glucose Cotransporter 2 Inhibitors: Mechanisms of Action and Various Effects
- Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
